These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3993288)

  • 21. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides.
    Denoël P; Godfroid F; Hermand P; Verlant V; Poolman J
    Vaccine; 2011 Sep; 29(38):6451-3. PubMed ID: 21315695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of pneumococcal polysaccharide vaccine in children.
    Obaro S; Leach A; McAdam KW
    Lancet; 1998 Aug; 352(9127):575. PubMed ID: 9716086
    [No Abstract]   [Full Text] [Related]  

  • 24. The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.
    Spencer BL; Shenoy AT; Orihuela CJ; Nahm MH
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pneumococcal surface protein A and new approaches for pneumococcal vaccine development].
    Vorob'ev DS; Semenova IB
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (6):107-13. PubMed ID: 22308742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal and systemic immunization with pneumococcal polysaccharide type 3, 4 and 14 in the rat.
    van den Dobbelsteen GP; Brunekreef K; Sminia T; van Rees EP
    Adv Exp Med Biol; 1995; 371B():1605-10. PubMed ID: 7502866
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.
    Austrian R
    J Infect Dis; 1977 Aug; 136 Suppl():S38-42. PubMed ID: 19543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serological purification of polysaccharide antigens from Streptococcus mutans serotypes a and d: characterization of multiple antigenic determinants.
    Linzer R; Mukasa H; Slade HD
    Infect Immun; 1975 Oct; 12(4):791-8. PubMed ID: 53200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal polysaccharide immunization in infants and children.
    Cowan MJ; Ammann AJ; Wara DW; Howie VM; Schultz L; Doyle N; Kaplan M
    Pediatrics; 1978 Nov; 62(5):721-7. PubMed ID: 31592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine.
    Sorensen RU; Leiva LE; Giangrosso PA; Butler B; Javier FC; Sacerdote DM; Bradford N; Moore C
    Pediatr Infect Dis J; 1998 Aug; 17(8):685-91. PubMed ID: 9726341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenetic analysis of the immune response to pneumococcal polysaccharide.
    Baxendale HE; Davis Z; White HN; Spellerberg MB; Stevenson FK; Goldblatt D
    Eur J Immunol; 2000 Apr; 30(4):1214-23. PubMed ID: 10760811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Planning for a second (23 valent) generation pneumococcal vaccine. With special reference to new developments in our understanding of the structure and biology of polysaccharides.
    Robbins JB; Schneerson R
    Bull Eur Physiopathol Respir; 1983; 19(2):215-26. PubMed ID: 6347282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New 23-valent pneumococcal vaccine in relation to pneumococcal serotypes in systemic and non-systemic disease.
    Smart LE; Dougall AJ; Girdwood RW
    J Infect; 1987 May; 14(3):209-15. PubMed ID: 3585032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological properties of an immunogenic pneumococcal subcellular preparation.
    Thompson HC; Eisenstein TK
    Infect Immun; 1976 Mar; 13(3):750-7. PubMed ID: 5373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of the pneumococcal serovar 3 erythrocyte antibody diagnostic agent for analyzing polysaccharide-containing preparations].
    Moshiashvili IIa; Vaneeva NP; Gruber IM
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Aug; (8):77-80. PubMed ID: 6207691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemistry and immunochemistry of the pneumococcal polysaccharide vaccine with special reference to cross-reactions and immunologic factors.
    Schiffman G
    Rev Infect Dis; 1981; 3 Suppl():S18-30. PubMed ID: 7025157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunochemical study of the type-specific polysaccharides of pneumococcus].
    Shagam NL; Vaneeva NP; Tsvetkova NV; Kuznetsova EM; Klimenko TV
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):70-3. PubMed ID: 6414201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.